JP6805232B2 - （１ｒ，２ｒ，５ｒ）−５−アミノ−２−メチルシクロヘキサノール塩酸塩の合成方法及びそれに有用な中間体 - Google Patents

（１ｒ，２ｒ，５ｒ）−５−アミノ−２−メチルシクロヘキサノール塩酸塩の合成方法及びそれに有用な中間体 Download PDF

Info

Publication number: JP6805232B2
Authority: JP; Japan
Prior art keywords: compound; formula; solvent; naoh; dcm
Prior art date: 2015-07-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2018503482A

Other languages

English (en)

Japanese (ja)

Other versions

JP2018521085A5 (fr

JP2018521085A (ja

Inventor

ジョセフコノリーテレンス

マンホン‐ワフ

ナガラジャンペリヤンディ

ラジェンディランチンナピライ

ヴェンカテスワルルジャスティ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Celgene Corp

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-24

Filing date

2016-07-22

Publication date

2020-12-23

2016-07-22 Application filed by Celgene Corp filed Critical Celgene Corp

2018-08-02 Publication of JP2018521085A publication Critical patent/JP2018521085A/ja

2019-08-22 Publication of JP2018521085A5 publication Critical patent/JP2018521085A5/ja

2020-12-23 Application granted granted Critical

2020-12-23 Publication of JP6805232B2 publication Critical patent/JP6805232B2/ja

Status Active legal-status Critical Current

2036-07-22 Anticipated expiration legal-status Critical

Links

GJIKAJOLWXMKEG-UHFFFAOYSA-N CC(CC1)=CCC1N Chemical compound CC(CC1)=CCC1N GJIKAJOLWXMKEG-UHFFFAOYSA-N 0.000 description 2
0 C[C@@](CC[C@](C1)N*)[C@@]1O Chemical compound C[C@@](CC[C@](C1)N*)[C@@]1O 0.000 description 2
PCOYCFJCVTWMFV-JTQLQIEISA-N CC(C)(C)OC(N[C@H]1CC=C(C)CC1)=O Chemical compound CC(C)(C)OC(N[C@H]1CC=C(C)CC1)=O PCOYCFJCVTWMFV-JTQLQIEISA-N 0.000 description 1
YOUXMVZSALAVJO-UHFFFAOYSA-N CC(CC1)=CCC1C(N)=O Chemical compound CC(CC1)=CCC1C(N)=O YOUXMVZSALAVJO-UHFFFAOYSA-N 0.000 description 1
OYOQOLNBTPTFEM-UHFFFAOYSA-N CC(CC1)=CCC1C(O)=O Chemical compound CC(CC1)=CCC1C(O)=O OYOQOLNBTPTFEM-UHFFFAOYSA-N 0.000 description 1
JNDBPUPULVCVFC-UHFFFAOYSA-N CC(CC1)=CCC1C(OC)=O Chemical compound CC(CC1)=CCC1C(OC)=O JNDBPUPULVCVFC-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/54—Preparation of compounds containing amino groups bound to a carbon skeleton by rearrangement reactions
- C07C209/58—Preparation of compounds containing amino groups bound to a carbon skeleton by rearrangement reactions from or via amides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/82—Purification; Separation; Stabilisation; Use of additives
- C07C209/86—Separation
- C07C209/88—Separation of optical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/40—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
- C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C67/347—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by addition to unsaturated carbon-to-carbon bonds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP2018503482A 2015-07-24 2016-07-22 （１ｒ，２ｒ，５ｒ）−５−アミノ−２−メチルシクロヘキサノール塩酸塩の合成方法及びそれに有用な中間体 Active JP6805232B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562196363P	2015-07-24	2015-07-24
US62/196,363		2015-07-24
PCT/US2016/043511 WO2017019487A1 (fr)	2015-07-24	2016-07-22	Procédés de synthèse de chlorhydrate de (1r,2r,5r)-5-amino-2-méthylcyclohexanol et intermédiaires utiles à cet effet

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2020200723A Division JP7165178B2 (ja)	2015-07-24	2020-12-03	（１ｒ，２ｒ，５ｒ）－５－アミノ－２－メチルシクロヘキサノール塩酸塩の合成方法及びそれに有用な中間体

Publications (3)

Publication Number	Publication Date
JP2018521085A JP2018521085A (ja)	2018-08-02
JP2018521085A5 JP2018521085A5 (fr)	2019-08-22
JP6805232B2 true JP6805232B2 (ja)	2020-12-23

Family

ID=57885143

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2018503482A Active JP6805232B2 (ja)	2015-07-24	2016-07-22	（１ｒ，２ｒ，５ｒ）−５−アミノ−２−メチルシクロヘキサノール塩酸塩の合成方法及びそれに有用な中間体
JP2020200723A Active JP7165178B2 (ja)	2015-07-24	2020-12-03	（１ｒ，２ｒ，５ｒ）－５－アミノ－２－メチルシクロヘキサノール塩酸塩の合成方法及びそれに有用な中間体

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2020200723A Active JP7165178B2 (ja)	2015-07-24	2020-12-03	（１ｒ，２ｒ，５ｒ）－５－アミノ－２－メチルシクロヘキサノール塩酸塩の合成方法及びそれに有用な中間体

Country Status (9)

Country	Link
US (4)	US10252981B2 (fr)
EP (2)	EP3795553B1 (fr)
JP (2)	JP6805232B2 (fr)
CN (1)	CN107922287B (fr)
AU (2)	AU2016297784B2 (fr)
CA (2)	CA3208587A1 (fr)
ES (2)	ES2994877T3 (fr)
MX (2)	MX385379B (fr)
WO (1)	WO2017019487A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3250557B1 (fr)	2015-01-29	2024-11-20	Signal Pharmaceuticals, LLC	Isotopologues de 2-(tert-butylamino)-4-((1r,3r,4r) -3-hydroxy-4-méthylcyclohexylamino)-pyrimidine-5-carboxamide
CN107922287B (zh)	2015-07-24	2021-04-09	细胞基因公司	合成(1r,2r,5r)-5-氨基-2-甲基环己醇盐酸盐的方法和其中可用的中间体
CN111848423B (zh) *	2019-04-30	2022-10-14	尚科生物医药（上海）有限公司	3-氧代环丁基氨基甲酸叔丁酯的制备方法

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2859239A (en)	1956-08-17	1958-11-04	Dow Chemical Co	Acrylic acid compounds
CH549339A (de)	1971-05-12	1974-05-31	Ciba Geigy Ag	Herbizides mittel.
US5763647A (en) *	1990-03-30	1998-06-09	Shionogi & Co., Ltd.	Preparation of optically active 1,4-bridged-cyclohexane carboxylic acid derivatives
CA2072270A1 (fr)	1991-06-26	1992-12-27	Joseph V. Koleske	Production d'esters cycloaliphatiques insatures, et derives de ceux-ci
EP1054004B1 (fr)	1997-12-15	2008-07-16	Astellas Pharma Inc.	Nouveaux derives de pyrimidine-5-carboxamide
ATE342892T1 (de)	1998-08-29	2006-11-15	Astrazeneca Ab	Pyrimidine verbindungen
ATE288420T1 (de)	1999-06-09	2005-02-15	Yamanouchi Pharma Co Ltd	Neuartige heterocyclische carboxamid-derivate
WO2000076980A1 (fr)	1999-06-10	2000-12-21	Yamanouchi Pharmaceutical Co., Ltd.	Nouveaux derives heterocycliques azotes ou leurs sels
WO2001000213A1 (fr)	1999-06-30	2001-01-04	Merck & Co., Inc.	Composes inhibiteurs de la src kinase
BR0013551A (pt)	1999-08-13	2003-06-17	Vertex Pharma	Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
WO2003082855A1 (fr)	2002-03-28	2003-10-09	Kyowa Hakko Kogyo Co., Ltd.	Agent anti-inflammatoire
EP1518855B1 (fr)	2002-06-28	2011-10-26	Astellas Pharma Inc.	Derive de diaminopyrimidinecarboxamide
HRP20050089B1 (hr)	2002-07-29	2015-06-19	Rigel Pharmaceuticals	Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
JPWO2004054617A1 (ja)	2002-12-13	2006-04-20	協和醗酵工業株式会社	中枢疾患の予防および／または治療剤
EP1586551A4 (fr) *	2003-01-16	2006-07-26	Toray Finechemicals Co Ltd	Procede de recuperation d'acides diacyltartarique optiquement actifs
MXPA05007503A (es)	2003-01-17	2005-09-21	Warner Lambert Co	Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US20040242613A1 (en)	2003-01-30	2004-12-02	Boehringer Ingelheim Pharmaceuticals, Inc.	Pyrimidine derivatives useful as inhibitors of PKC-theta
PT1660458E (pt)	2003-08-15	2012-04-27	Novartis Ag	2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
RU2006107578A (ru)	2003-09-24	2007-10-27	Вайет Холдингз Корпорейшн (Us)	6-арилпиримидин, применяемый в качестве противоракового агента
WO2005095382A1 (fr)	2004-03-30	2005-10-13	Kyowa Hakko Kogyo Co., Ltd.	Agent anti tumoral
JP2008505910A (ja)	2004-07-08	2008-02-28	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	Ｐｋｃ−シータのインヒビターとして有用なピリミジン誘導体
JP2008512429A (ja)	2004-09-10	2008-04-24	ニコメッドゲゼルシャフトミットベシュレンクテルハフツング	ロフルミラストとｓｙｋインヒビターとの組合せ物並びにその使用方法
CA2579007A1 (fr)	2004-09-10	2006-03-16	Altana Pharma Ag	Combinaison de ciclesonide et d'inhibiteur de syk et procedes d'utilisation
JP2006124387A (ja)	2004-09-30	2006-05-18	Taisho Pharmaceut Co Ltd	新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
JP5046943B2 (ja)	2004-09-30	2012-10-10	テイボテク・フアーマシユーチカルズ	Ｈｉｖ阻害性５−置換ピリミジン
WO2006091737A1 (fr)	2005-02-24	2006-08-31	Kemia, Inc.	Modulateurs de l'activite de gsk-3
US20110098301A1 (en)	2005-03-10	2011-04-28	Bayer Healthcare Llc	Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders
WO2007032445A1 (fr)	2005-09-16	2007-03-22	Kyowa Hakko Kogyo Co., Ltd.	Inhibiteurs de la protéine kinase
WO2008009458A1 (fr)	2006-07-21	2008-01-24	Novartis Ag	Composés de 2,4-di(arylamino)-pyrimidine-5-carboxamide comme inhibiteurs des jak kinases
US8188113B2 (en)	2006-09-14	2012-05-29	Deciphera Pharmaceuticals, Inc.	Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20080139531A1 (en)	2006-12-04	2008-06-12	Alcon Manufacturing Ltd.	Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
CL2007003693A1 (es)	2006-12-22	2008-06-27	Actelion Pharmaceuticals Ltd	Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
CN101678215B (zh)	2007-04-18	2014-10-01	辉瑞产品公司	用于治疗异常细胞生长的磺酰胺衍生物
WO2008132505A1 (fr)	2007-04-27	2008-11-06	Astrazeneca Ab	Nouveaux dérivés de n' - (phényl) -n- (morpholin-4-yl-pyridin-2-yl) -pyrimidine-2, 4-diaminepyrimidine en tant qu'inhibiteurs de ephb4 kinase pour le traitement d'états prolifératifs
EA201000101A1 (ru)	2007-07-16	2010-08-30	Астразенека Аб	Производные пиримидина 934
CN101903357A (zh)	2007-07-17	2010-12-01	里格尔药品股份有限公司	作为pkc抑制剂的环状胺取代的嘧啶二胺
JP5269444B2 (ja) *	2008-03-11	2013-08-21	東ソー・ファインケム株式会社	固体ルイス酸触媒、それを用いたディールスアルダー付加物の製造方法
SG165655A1 (en)	2008-04-16	2010-11-29	Portola Pharm Inc	2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
HRP20161310T1 (hr)	2008-04-16	2016-12-02	Portola Pharmaceuticals, Inc.	2,6-diamino-pirimidin-5-il-karboksamidi kao inhibitori syk ili jak kinaza
AU2009238590A1 (en)	2008-04-22	2009-10-29	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
CA2719868A1 (fr)	2008-04-29	2009-11-05	F. Hoffmann-La Roche Ag	Pyrimidinyle pyridones inhibiteurs de jnk
MX353308B (es)	2008-05-21	2018-01-08	Ariad Pharma Inc	Derivados fosforosos como inhibidores de cinasa.
PE20100087A1 (es)	2008-06-25	2010-02-08	Irm Llc	Compuestos y composiciones como inhibidores de cinasa
NZ603525A (en)	2008-06-27	2015-02-27	Celgene Avilomics Res Inc	Pyrimidine based compound and uses thereof
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
JP5644499B2 (ja)	2008-09-01	2014-12-24	アステラス製薬株式会社	２，４−ジアミノピリミジン化合物
EP2159220A1 (fr)	2008-09-02	2010-03-03	Nabriva Therapeutics AG	Composés organiques
TWI453207B (zh) *	2008-09-08	2014-09-21	Signal Pharm Llc	胺基三唑并吡啶，其組合物及使用其之治療方法
US20110166161A1 (en)	2008-09-18	2011-07-07	Astellas Pharma Inc.	Heterocyclic carboxamide compounds
TW201016676A (en)	2008-10-03	2010-05-01	Astrazeneca Ab	Heterocyclic derivatives and methods of use thereof
US9234178B2 (en)	2008-10-31	2016-01-12	Janssen Biotech, Inc.	Differentiation of human pluripotent stem cells
US8513242B2 (en)	2008-12-12	2013-08-20	Cystic Fibrosis Foundation Therapeutics, Inc.	Pyrimidine compounds and methods of making and using same
EP2375899B1 (fr)	2009-01-12	2015-02-25	Array Biopharma Inc.	Composés contenant de la pipéridine et leur utilisation dans le traitement du diabète
US8470835B2 (en)	2009-01-13	2013-06-25	Glaxo Group Limited	Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase
JP5781943B2 (ja)	2009-01-21	2015-09-24	ライジェルファーマシューティカルズ，インコーポレイテッド	炎症性疾患、自己免疫疾患または増殖性疾患の治療に有用なｎ２−（３−ピリジルまたはフェニル）−ｎ４−（４−ピペリジル）−２，４−ピリミジンジアミン誘導体
US8367689B2 (en)	2009-05-06	2013-02-05	Portola Pharmaceuticals, Inc.	Inhibitors of JAK
LT3009428T (lt)	2009-05-08	2018-04-10	Astellas Pharma Inc.	Diamino heterociklinis karboksamido junginys
JP2012148977A (ja)	2009-05-20	2012-08-09	Astellas Pharma Inc	アミノシクロヘキシルアルキル基を有する２，４−ジアミノピリミジン化合物
EP2440548A1 (fr)	2009-06-10	2012-04-18	Abbott Laboratories	2-(lh-pyrazol-4-ylamino)-pyrimidine en tant qu'inhibiteurs de kinase
JP2012197231A (ja)	2009-08-06	2012-10-18	Oncotherapy Science Ltd	Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
WO2011065800A2 (fr)	2009-11-30	2011-06-03	주식회사 오스코텍	Dérivé de pyrimidine, procédé de préparation de ce dérivé et composition pharmaceutique contenant ce dérivé
EP2507227B1 (fr)	2009-12-01	2014-10-08	Rigel Pharmaceuticals, Inc.	Tetrazolones comme inhibiteurs de la protéine kinase c et leurs utilisations
EP2582671A4 (fr) *	2010-06-17	2014-02-26	Reddys Lab Ltd Dr	Procédé pour la préparation d'un unique énantiomère du dichlorhydrate de 3-aminopipéridine
JP6035238B2 (ja)	2010-07-21	2016-11-30	ライジェルファーマシューティカルズ，インコーポレイテッド	プロテインキナーゼｃ阻害剤およびその使用
US8580805B2 (en)	2010-08-31	2013-11-12	Hubert Maehr	Pyrimidine carboxamide derivatives
WO2012044936A1 (fr)	2010-09-30	2012-04-05	Portola Pharmaceuticals, Inc.	Polythérapie avec du 4-(3-(2h-1,2,3-triazol-2-yl)phénylamino)-2-((1r,2s)-2- aminocyclohexylamino)pyrimidine-5-carboxamide
EP2621489A1 (fr)	2010-09-30	2013-08-07	Portola Pharmaceuticals, Inc.	Combinaisons de 4-(cyclopropylamino)-2-(4-(4-(éthylsulfonyl)pipérazin-1-yl)phénylamino)pyrimidine-5-carboxamide et de fludarabine
US9139534B2 (en)	2011-04-22	2015-09-22	Signal Pharmaceuticals, Llc	Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
WO2014019166A1 (fr) *	2012-08-01	2014-02-06	上海威智医药科技有限公司	Procédé de production industrielle pour composé borane de haute activité
JP2014031327A (ja) *	2012-08-02	2014-02-20	Kaneka Corp	光学活性シス−２−アミノ−シクロヘキサンカルボン酸誘導体およびその前駆体の製造法
US9556126B2 (en)	2013-12-20	2017-01-31	Signal Pharmaceuticals, Llc	Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
NZ715903A (en)	2014-01-30	2017-06-30	Signal Pharm Llc	Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
TWI523838B (zh) *	2014-03-21	2016-03-01	Far Eastern New Century Corp	Terephthalic acid and 4-methyl-3-cyclohexene-1-carboxylic acid Ester preparation method
US9512124B2 (en)	2014-10-06	2016-12-06	Signal Pharmaceuticals, Llc	Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
US9513297B2 (en)	2014-12-16	2016-12-06	Signal Pharmaceuticals, Llc	Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
CN107108524A (zh)	2014-12-16	2017-08-29	西格诺药品有限公司	2‑(叔丁基氨基)‑4‑((1r,3r,4r)‑3‑羟基‑4‑甲基环己基氨基)‑嘧啶‑5‑甲酰胺的配制物
EP3250557B1 (fr)	2015-01-29	2024-11-20	Signal Pharmaceuticals, LLC	Isotopologues de 2-(tert-butylamino)-4-((1r,3r,4r) -3-hydroxy-4-méthylcyclohexylamino)-pyrimidine-5-carboxamide
CN107922287B (zh) *	2015-07-24	2021-04-09	细胞基因公司	合成(1r,2r,5r)-5-氨基-2-甲基环己醇盐酸盐的方法和其中可用的中间体

2016
- 2016-07-22 CN CN201680043308.1A patent/CN107922287B/zh active Active
- 2016-07-22 ES ES20193348T patent/ES2994877T3/es active Active
- 2016-07-22 CA CA3208587A patent/CA3208587A1/fr active Pending
- 2016-07-22 US US15/746,853 patent/US10252981B2/en active Active
- 2016-07-22 CA CA2993173A patent/CA2993173C/fr active Active
- 2016-07-22 AU AU2016297784A patent/AU2016297784B2/en active Active
- 2016-07-22 EP EP20193348.8A patent/EP3795553B1/fr active Active
- 2016-07-22 WO PCT/US2016/043511 patent/WO2017019487A1/fr not_active Ceased
- 2016-07-22 MX MX2020001720A patent/MX385379B/es unknown
- 2016-07-22 ES ES16831114T patent/ES2819374T3/es active Active
- 2016-07-22 EP EP16831114.0A patent/EP3325432B1/fr active Active
- 2016-07-22 MX MX2018001004A patent/MX2018001004A/es active IP Right Grant
- 2016-07-22 JP JP2018503482A patent/JP6805232B2/ja active Active
2019
- 2019-01-28 US US16/258,802 patent/US10774033B2/en active Active
2020
- 2020-08-13 US US16/992,219 patent/US11192847B2/en active Active
- 2020-12-03 JP JP2020200723A patent/JP7165178B2/ja active Active
2021
- 2021-03-09 AU AU2021201493A patent/AU2021201493B2/en active Active
- 2021-11-03 US US17/518,552 patent/US11780801B2/en active Active

Also Published As

Publication number	Publication date
ES2994877T3 (en)	2025-02-03
MX2018001004A (es)	2018-06-07
AU2016297784B2 (en)	2020-12-24
AU2016297784A1 (en)	2018-02-08
US20220234990A1 (en)	2022-07-28
US20180215700A1 (en)	2018-08-02
CA2993173C (fr)	2023-10-03
EP3325432A4 (fr)	2019-04-24
CN107922287B (zh)	2021-04-09
EP3795553B1 (fr)	2024-05-15
EP3325432A1 (fr)	2018-05-30
CA2993173A1 (fr)	2017-02-02
US20190152893A1 (en)	2019-05-23
US11192847B2 (en)	2021-12-07
HK1255553A1 (en)	2019-08-23
WO2017019487A1 (fr)	2017-02-02
US10774033B2 (en)	2020-09-15
US11780801B2 (en)	2023-10-10
AU2021201493B2 (en)	2022-07-14
JP2018521085A (ja)	2018-08-02
EP3325432B1 (fr)	2020-09-02
CN107922287A (zh)	2018-04-17
JP7165178B2 (ja)	2022-11-02
EP3795553A1 (fr)	2021-03-24
US10252981B2 (en)	2019-04-09
ES2819374T3 (es)	2021-04-15
CA3208587A1 (fr)	2017-02-02
MX385379B (es)	2025-03-18
JP2021046426A (ja)	2021-03-25
US20200369600A1 (en)	2020-11-26
MX2020001720A (es)	2021-08-13
AU2021201493A1 (en)	2021-03-25

Legal Events

Date	Code	Title	Description
2019-07-08	A524	Written submission of copy of amendment under article 19 pct	Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20190708
2019-07-08	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190708
2020-06-01	A977	Report on retrieval	Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200528
2020-06-09	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200609
2020-09-08	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200908
2020-09-28	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200909
2020-10-26	TRDD	Decision of grant or rejection written
2020-11-04	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201104
2020-12-07	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201203
2020-12-07	R150	Certificate of patent or registration of utility model	Ref document number: 6805232 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2023-11-29	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-12-05	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2025-12-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250

Publication	Publication Date	Title
JP4674088B2 (ja)	2011-04-20	Ｇｓｋ３で選択的な阻害作用を示す新規な化合物
JP7165178B2 (ja)	2022-11-02	（１ｒ，２ｒ，５ｒ）－５－アミノ－２－メチルシクロヘキサノール塩酸塩の合成方法及びそれに有用な中間体
RS59909B1 (sr)	2020-03-31	Benzoimidazol-2-il pirimidinski modulatori histaminskog h4 receptora
EP3752497B1 (fr)	2024-07-17	Inhibiteurs d'hat p300/cbp
UA105377C2 (uk)	2014-05-12	Заміщені похідні індазола і азаіндазола як модулятори гамма-секретази
CN106573907B (zh)	2020-09-08	喹啉衍生物及其用于神经退化性疾病的用途
JP2020183437A (ja)	2020-11-12	２−（ｔｅｒｔ−ブチルアミノ）−４−（（１Ｒ，３Ｒ，４Ｒ）−３−ヒドロキシ−４−メチルシクロヘキシルアミノ）−ピリミジン−５−カルボキサミドの固体形態、その組成物、及びその使用方法
AU2013235729A1 (en)	2014-10-09	Compositions and methods for inhibition of cathepsins
AU2015367396C1 (en)	2019-05-16	3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors
WO2021062036A1 (fr)	2021-04-01	Inhibiteurs de jak
HK40040730B (en)	2024-12-20	Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
HK40040730A (en)	2021-08-06	Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
HK1255553B (en)	2021-02-19	Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
JP2006232671A (ja)	2006-09-07	新規セレナゾリン誘導体
HK40122633A (zh)	2025-10-03	Jak抑制剂类似物、制剂及其用途
KR20220010493A (ko)	2022-01-25	효소 11-베타 탈수소효소 유형 1(11β-HSD1)의 환원효소 활성의 효과적이고 선택적인 저해제로 사용되기에 적합한 아다만틸 옥사디아졸의 유도체 및 그 약학적으로 허용가능한 용매화물, 수화물 및 염, 이를 포함하는 약학적 조성물, 합성 방법